GLP1R and peripheral arterial disease: Despite the documented CV benefit and the availability of targeted guidelines, rates of real-life prescription of GLP-1 RA and SGLT2i in patients with T2D and PAD are suboptimal than expected, accounting for a minimum of <9% to a maximum of 22% in comparison to 75% and 56% of antiplatelets and statins, respectively [162,163,164].